Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,002 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
Ogura M, Itoh K, Ishizawa K, Kobayashi Y, Tobinai K, Kinoshita T, Hirano M, Ueda R, Shibata T, Nakamura S, Tsukasaki K, Hotta T, Shimoyama M, Morishima Y; Lymphoma Study Group (LSG) of Japan Clinical Oncology Group (JCOG). Ogura M, et al. Among authors: itoh k. Leuk Lymphoma. 2013 Jan;54(1):46-52. doi: 10.3109/10428194.2012.705000. Epub 2012 Aug 21. Leuk Lymphoma. 2013. PMID: 22712838 Clinical Trial.
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.
Tobinai K, Ishizawa K, Ogura M, Itoh K, Morishima Y, Ando K, Taniwaki M, Watanabe T, Yamamoto J, Uchida T, Nakata M, Terauchi T, Nawano S, Matsusako M, Hayashi M, Hotta T. Tobinai K, et al. Among authors: itoh k. Cancer Sci. 2009 Oct;100(10):1951-6. doi: 10.1111/j.1349-7006.2009.01247.x. Epub 2009 Jun 17. Cancer Sci. 2009. PMID: 19594547 Free PMC article. Clinical Trial.
Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas.
Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, Yamaguchi M, Kurosawa M, Tsukasaki K, Kasai M, Tobinai K, Kaba H, Mukai K, Nakamura S, Ohshima K, Hotta T, Shimoyama M. Watanabe T, et al. Among authors: itoh k. Leuk Lymphoma. 2010 May;51(5):813-21. doi: 10.3109/10428191003721359. Leuk Lymphoma. 2010. PMID: 20367565
Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results.
Tobinai K, Ogura M, Itoh K, Kinoshita T, Hotta T, Watanabe T, Morishima Y, Igarashi T, Terauchi T, Ohashi Y; All Collaborators of the IDEC-C2B8 Study Group in Japan. Tobinai K, et al. Among authors: itoh k. Cancer Sci. 2010 Dec;101(12):2579-85. doi: 10.1111/j.1349-7006.2010.01703.x. Cancer Sci. 2010. PMID: 20942866 Free PMC article. Clinical Trial.
Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).
Ogura M, Itoh K, Kinoshita T, Fukuda H, Takenaka T, Ohtsu T, Kagami Y, Tobinai K, Okamoto M, Asaoku H, Sasaki T, Mikuni C, Hirano M, Chou T, Ohnishi K, Ohno H, Nasu K, Okabe K, Ikeda S, Nakamura S, Hotta T, Shimoyama M. Ogura M, et al. Among authors: itoh k. Int J Hematol. 2010 Dec;92(5):713-24. doi: 10.1007/s12185-010-0712-8. Epub 2010 Nov 16. Int J Hematol. 2010. PMID: 21076995 Clinical Trial.
Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508.
Kagami Y, Itoh K, Tobinai K, Fukuda H, Mukai K, Chou T, Mikuni C, Kinoshita T, Fukushima N, Kiyama Y, Suzuki T, Sasaki T, Watanabe Y, Tsukasaki K, Hotta T, Shimoyama M, Ogura M; Lymphoma Study Group of the Japan Clinical Oncology Group. Kagami Y, et al. Among authors: itoh k. Int J Hematol. 2012 Jul;96(1):74-83. doi: 10.1007/s12185-012-1101-2. Epub 2012 Jun 3. Int J Hematol. 2012. PMID: 22661011 Clinical Trial.
Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study - JCOG0108A.
Kinoshita T, Watanabe T, Itoh K, Yoshimura K, Tobinai K, Ogura M, Yamaguchi M, Kurosawa M, Imaizumi Y, Ota S, Kaba H, Mukai K, Nakamura S, Ohshima K, Hotta T, Tsukasaki K, Nagai H, Shimoyama M. Kinoshita T, et al. Among authors: itoh k. J Clin Exp Hematop. 2021;61(1):35-41. doi: 10.3960/jslrt.20062. J Clin Exp Hematop. 2021. PMID: 33731548 Free PMC article.
Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma.
Tobinai K, Watanabe T, Ogura M, Morishima Y, Hotta T, Ishizawa K, Itoh K, Okamoto S, Taniwaki M, Tsukamoto N, Okumura H, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Hayashi M, Endo K. Tobinai K, et al. Among authors: itoh k. Cancer Sci. 2009 Jan;100(1):158-64. doi: 10.1111/j.1349-7006.2008.00999.x. Epub 2008 Oct 24. Cancer Sci. 2009. PMID: 19018755 Free article. Clinical Trial.
Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab.
Tobinai K, Watanabe T, Tanimoto K, Maruyama D, Nakata M, Itoh K, Morishima Y, Ogura M, Usui N, Kasai M, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y. Tobinai K, et al. Among authors: itoh k. Cancer Sci. 2009 Jul;100(7):1344-50. doi: 10.1111/j.1349-7006.2009.01162.x. Epub 2009 Apr 21. Cancer Sci. 2009. PMID: 19432900 Free article. Clinical Trial.
4,002 results